1599P - Ambulatory patients with metastatic or locally advanced cancer: is body mass index ≥ 35 a risk factor for thromboembolism also in European countri...

Date 01 October 2012
Event ESMO Congress 2012
Session Poster presentation III
Topics Supportive measures
Aetiology, epidemiology, screening and prevention
Basic Scientific Principles
Presenter Sandro Barni
Authors S. Barni1, R. Labianca2, G. Gasparini3, E. Bonizzoni4, F. Petrelli5, T. Perrone6, M. Verso7
  • 1Azienda Ospedaliera Treviglio-Caravaggio, 24047 - Treviglio/IT
  • 2Oncology And Hematolody Department, Ospedali Riuniti –, Bergamo/IT
  • 3Oncology Department, San Filippo Neri Hospital, Rome/IT
  • 4Institute Of Medical Statistics And Biometry, University of Milan, Milan/IT
  • 5Uo Oncologia, Azienda Ospedaliera Treviglio-Caravaggio, 24047 - Treviglio/IT
  • 6Medical Affair Department, Italfarmaco S.p.A., Cinisello Balsamo/IT
  • 7Internal And Vascular Medicine—stroke Unit, University of Perugia, Perugia/IT



Five variables (site of cancer, platelet count, haemoglobin level, leukocyte count and body mass index [BMI]) define the Khorana risk score, predicting the high (≥ 3), the moderate (1-2) and the low (0) risk of thromboembolic events (TE) in cancer outpatients. This score has validated BMI ≥ 35 as a risk factors for TE in the USA.


The aim of our retrospectively study was to evaluate the incidence of a BMI ≥ 35 (obesity of second and third class), a BMI ≥ 30 (obesity of all classes) and a BMI ≥ 25 (all forms of overweight) among 1150 ambulatory cancer patients receiving chemotherapy enrolled in the PROTECHT study: a randomized, double-blind, placebo-controlled study, evaluating the efficacy (incidence of symptomatic TE) of subcutaneous injections of nadroparin (3800 IU anti-Xa once a day). We evaluated also the distribution of TE among the three BMI categories.


are reported in the table below as percentage and (Number of patients) for BMI distribution and number of detected TE for each BMI class:

BMI ≥ 35 BMI ≥30 BMI ≥25
Treatment arm Pts TE Pts TE Pts TE
PLACEBO 381 pts 1.3 (5) 1 13.4 (51) 2 51.2 (195) 5
NADROPARIN 769 pts 2.6 (20) 0 14.0 (108) 1 49.0 (377) 9


In our study nearly 50% of patients with metastatic or locally advanced diagnosis of cancer are overweight and more than 25% of them are obese. The incidence of BMI ≥ 35 in a European cancer population seems to be negligible, otherwise all classes of overweight seems to be related to a higher risk of TE. A formal study is needed to evaluate the risk of all BMI classes as independent risk factors of TE among cancer patients.


T. Perrone: TP is employee of Italfarmaco S.p.A.

All other authors have declared no conflicts of interest.